{"id":"NCT00922480","sponsor":"Boryung Pharmaceutical Co., Ltd","briefTitle":"Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients","officialTitle":"A Randomized, Double-blind, Losartan-controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg~120mg in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2009-07","completion":"2009-09","firstPosted":"2009-06-17","resultsPosted":"2018-02-13","lastUpdate":"2018-04-10"},"enrollment":506,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Fimasartan","otherNames":["A657-BR-CT"]},{"type":"DRUG","name":"Losartan (Control)","otherNames":["Cozar"]}],"arms":[{"label":"2","type":"ACTIVE_COMPARATOR"},{"label":"1","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657â€¢K) 60 mg\\~120 mg in patients with mild to moderate essential hypertension.","primaryOutcome":{"measure":"Diastolic Blood Pressure Change","timeFrame":"baseline and 12 weeks","effectByArm":[{"arm":"Control: Losartan / Week 12 -ITT","deltaMin":-8.56,"sd":7.72},{"arm":"Test: Fimasartan / Week 12 -ITT","deltaMin":-11.26,"sd":7.53}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22381711","21740078"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":250},"commonTop":["Headache","Dizziness","Nasopharyngitis","Upper respiratory tract infection","Dyspepsia"]}}